Join Professor David Wheeler and experts from Europe and Canada as they explore key challenges in the diagnosis and management of chronic kidney disease (CKD), including the role of newer antidiabetic agents.
A multidisciplinary panel comprising a nephrologist, endocrinologist, cardiologist and primary care physician explore the benefits of collaborative working, supporting your clinical practice for better integrated care and outcomes for patients with CKD.
David Wheeler is Professor of Kidney Medicine at University College London, UK, and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients with chronic kidney disease.
Professor Wheeler’s other roles include Honorary Professorial Fellow of The George Institute and Chair of the International Society of Nephrology Advancing Clinical Trials network. He has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. In the UK, he is National Institute of Health Research (NIHR) Renal Specialty Lead and Co-Medical Director of the North Thames NIHR Clinical Research Network.
David Wheeler discloses the following interests: Ongoing consultancy arrangement with AstraZeneca. Honoraria from Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Napp, Mundipharma, and MSD.
Paola Fioretto is Professor in Medicine at the University of Padova, Italy. She started her research on renal physiology in diabetes and, during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes. Among her contributions to the understanding of diabetic kidney disease are the descriptions of the heterogeneity in the structural lesions underlying renal dysfunction in type 2 diabetes, and of reversal of established diabetic glomerulopathy lesions in patients with type 1 diabetes after pancreas transplantation.
Professor Fioretto’s research interest includes the effects of glucose-lowering therapies on the development and progression of diabetic kidney disease.
She has received several awards, including the Albert Renold award from the EASD (European Association for the Study of Diabetes), a Career Development Award from JDFI, the Morgagni Joung Investigator Award, the Novartis Joung Investigator, the Italian Society of Diabetology Award, and the Golgi Prize from the EASD. She has been Vice President of the EASD (2014-2017), and President of the European Diabetic Nephropathy Study Group of the EASD (2005-2007). She has published over 180 papers and 30 book chapters.
Paola Fioretto discloses the following interests: Fees for advisory board/lectures from AstraZeneca, Boehringer-Ingelhaim, Lilly, Mundipharma, Bayer.
Shelley Zieroth joined the Section of Cardiology at St Boniface Hospital in Winnipeg in July 2006. She is currently an Associate Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for the Winnipeg Regional Health Authority, Cardiac Sciences Program.
Dr Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
She is involved in several heart failure clinical trials as a PI, is National Lead for EMPULSE, DETERMINE and FINE-ARTS clinical trials and she is on the Steering Committee of PARAGLIDE. Her area of research examines the efficacy of new treatments, including food derived bioactives, in heart failure. She is President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panels for both the Heart Failure and Heart Transplant Guidelines. She is also Co-Chair of Canada’s largest annual heart failure meeting, HF Update. Her current passion is working with national and provincial patient advocacy groups and primary care to operationalize hub and spoke models of heart failure care.
Dr Zieroth is actively engaged in Social Media and promotes #cardiotwitter for its rapid access to clinical trial data, publications and free online access to medical education. It is through this engagement that Dr. Zieroth has become recognized as a global supporter and sponsor of women in medicine and cardiology.
Shelley Zieroth discloses the following interests: Consultancy/Advisory board with Abbott, Akcea, AstraZeneca, Amgen, Alnylam, Boehringer-Ingelhaim, Merck, Novartis, Pfizer, Servier; speaker for AstraZeneca, Boehringer-Ingelhaim, Eli-Lilly, Novartis, Servier; Clinical trials for/research and education grants from Amgen, AstraZeneca, Bayer, Boehringer-Ingelhaim, Eidos, Merck, Novartis, and Servier.
Francesc Xavier Cos is a general practitioner graduated in 1997 and currently working as a GP in Sant Martí Primary Health Centres (Catalonian National Health Service) and Head of innovation in Primary Care Barcelona-city in Primary Care Barcelona, Spain. His main areas of interest are Research and Education in Primary Care with a special emphasis on the Diabetes field.
Dr Cos is a member of the Primary Care University Research Institute Jordi Gol and currently its European representative in Diabetes and Endocrine disorders. At this research institution he is an active member in 2 working groups: Diabetes Prevention and Epidemiological Database analysis. He was also the Spanish national representative of the European General Practice Research Network, WONCA Europe research Group (www.egprn.org) on behalf of the Spanish Primary Care society (www.semfyc.es) from 2009 to 2015. He started his activities on Diabetes at GEDAPS “Primary Care Diabetes Study Group” (www.redgdps.org) in1997, working on Diabetes treatment.
In Spain he has been working in many institutional projects for the Catalonian Health Department, (Type 2 Diabetes treatment Guidelines, SBMG recommendations and the Diabetes Expert Patient Programme). He is regularly invited to participate in national and international meetings to lecture as an expert on Diabetes in Primary Care or to develop and conduct educational activities. He also participates in many advisory boards and expert groups.
Dr Cos is currently working in various research projects in Diabetes prevention (DP Transfers), CATRisc, DE-PLAN, DISCOVER, LadyDiab, VERIFY and OBINDIAB. His unit has recently been involved in many randomized clinical trials (Dapagliflozin, Lixisenatide, Early treatment with MET+Vilda). He is also involved in the academic field as an Associate Professor at the medicine department of the Universitat Autonoma de Barcelona since 2009 and he is currently an associate editor of the Primary Care Diabetes journal. In 2009 he was elected as vice chairman of the Primary Care Diabetes Europe (www.pcdeurope.org) and since February 2016 as Chairman elect. In February 2017 he was appointed as Chairman of PCDE for a term of 4 years
Francesc Xavier Cos discloses the following interests: Consultancy for AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk and Sanofi Diabetes, and Sanofi Pasteur; research Support from AstraZeneca, Novartis, SANOFI, Boehringer Ingelheim; speakers bureau for AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, Sanofi Diabetes, Sanofi Pasteur.